Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, and Albert Einstein College of Medicine of Yeshiva University, a research-intensive medical school in Bronx, NY, started development of an antibody construct labeled with actinium 225 using a novel technology that potentially allows for the expansion of use of the company’s proprietary platform and enables further manufacturing improvements of alpha therapy technology-based drug candidates. The first antibody to be labeled using the new technology has potential to be used in the field of hematology/oncology. The company says preclinical studies of the new technology have demonstrated improvements in the product’s manufacturing while maintaining biological integrity and properties of labeled antibodies.

In addition to making the manufacturing process more time and cost efficient, the new technology is designed to allow for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.

“Adding even more possibilities to our already versatile platform further expands the reach of our technology,” said Kaushik Dave, Actinium’s president and chief executive officer. “As we move ahead we expect to be able to focus on more and more antigens including those that have been considered too difficult to target until now.”

Pending successful results of the preclinical work at Einstein, collaborating parties intend to continue development in clinical trials.